Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Lowered by LSV Asset Management

LSV Asset Management decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,509,889 shares of the biopharmaceutical company's stock after selling 166,860 shares during the quarter. Gilead Sciences makes up about 0.8% of LSV Asset Management's investment portfolio, making the stock its 21st largest position. LSV Asset Management owned 0.44% of Gilead Sciences worth $378,033,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. boosted its position in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 238 shares during the period. Private Wealth Management Group LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $29,000. Palisade Asset Management LLC bought a new position in Gilead Sciences during the first quarter worth $29,000. Sachetta LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $30,000. Finally, Financial Connections Group Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $34,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Royal Bank of Canada raised their target price on Gilead Sciences from $72.00 to $74.00 and gave the stock a "sector perform" rating in a research note on Wednesday. Truist Financial increased their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a report on Thursday, August 15th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Robert W. Baird reaffirmed a "neutral" rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Finally, Raymond James upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 target price for the company in a research report on Monday, July 8th. Twelve investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $82.06.

Insider Activity

In other news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company's stock, valued at $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company's stock, valued at $8,506,146.42. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 0.1 %

NASDAQ GILD traded down $0.05 on Friday, hitting $78.72. 9,220,980 shares of the company were exchanged, compared to its average volume of 7,163,236. The company has a market cap of $98.07 billion, a PE ratio of 218.67, a PEG ratio of 2.74 and a beta of 0.18. The stock has a fifty day moving average of $74.06 and a 200-day moving average of $70.55. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analysts' expectations of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. As a group, analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.91%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences's payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.